What if cancer could be predicted and prevented using digital twins?

ABout US

CancerTwin’s background

Cancer prognosis is often worsened because of lack of biomarkers for early diagnosis. The main reason is complexity and heterogeneity of cancer: each tumour involves altered interactions among thousands of genes across multiple cell types, varying between patients and over time. Searching for suitable biomarkers is thus like finding many needles in many haystacks. As highlighted by us in a recent Nature Biotechnology article, digital twin technology can lead to reliable biomarkers for early cancer diagnosis.

CancerTwin aims to apply digital twin technoloy to find such biomarkers. CancerTwin builds on decades of research at Karolinska Institutet and partner institutions in Sweden, the UK, and the US. Feasibility is supported by multiple studies, one recognized as a “success story” in the European Roadmap for the Virtual Human Twin

Our Mission

How can digital twins contribute to early cancer diagnostics?

CancerTwin constructs digital twin (DT) models of tumors on scales ranging from whole diagnostic groups to subtypes and individuals. The construction is based on combining routine clinical- and multi-omics data down to the spatial single cell level. We use different computational methods to prioritize early mechanisms, biomarkers and drug targets.

A recent example attracted global media attention: CancerTwin is a spinoff from the Swedish Digital Twin Consortium and the Medical Digital Twin Research Group at the Karolinska Institute. This website has detailed information, including publications: sdtc.se

Our Team

Cancertwin Inc

Our dedicated team

Mikael Benson

MD, PhD, CEO

Thorunn Gudmundsdottir

CFO

Elisabet Benson

CTO